ArticleThe American journal of tropical medicine and hygiene2019
High Rates of Premature and Potentially Preventable Death among Patients Surviving Melioidosis in Tropical Australia.
Article in The American journal of tropical medicine and hygiene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Drug screening to identify compounds to eliminateiScience · 2026Article
- The Association Between Statin Therapy and the Subsequent Clinical Course of Patients With Melioidosis.Journal of tropical medicine · 2025Article
- The characteristics and clinical course of patients with melioidosis and cancer.PLoS neglected tropical diseases · 2024Article
- Bone and joint infections due to melioidosis; diagnostic and management strategies to optimise outcomes.PLoS neglected tropical diseases · 2024Article
- The Epidemiological, Clinical, and Microbiological Features of Patients withTropical medicine and infectious disease · 2023Article
- Case Report: Vagal Nerve Neuritis Associated with Pulmonary Melioidosis Provides Potential Insights into the Pathophysiology of Neuromelioidosis.The American journal of tropical medicine and hygiene · 2023Article
- DNase I and chitosan enhance efficacy of ceftazidime to eradicate Burkholderia pseudomallei biofilm cells.Scientific reports · 2023Article
- A novel lytic phage potentially effective for phage therapy against Burkholderia pseudomallei in the tropics.Infectious diseases of poverty · 2022Article
- Examination of the independent contribution of rheumatic heart disease and congestive cardiac failure to the development and outcome of melioidosis in Far North Queensland, tropical Australia.PLoS neglected tropical diseases · 2022Article
- The seasonality of infections in tropical Far North Queensland, Australia: A 21-year retrospective evaluation of the seasonal patterns of six endemic pathogens.PLOS global public health · 2022Article
- Melioidosis-a disease of socioeconomic disadvantage.PLoS neglected tropical diseases · 2021Article
- The temporospatial epidemiology of rheumatic heart disease in Far North Queensland, tropical Australia 1997-2017; impact of socioeconomic status on disease burden, severity and access to care.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the in-hospital mortality of Australian patients with melioidosis continues to decline, the ensuing clinical course of survivors is poorly described. Between January 1, 1998, and January 31, 2019, 228 patients in Cairns, tropical Australia, survived their hospitalization with melioidosis; however, 52 (23%) subsequently died. Death occurred at a median of 3.8 years after discharge, with patients dying at a mean age of 59 years. Only 1/27 (4%) without predisposing conditions for melioidosis died during follow-up, versus 51/201 (25%) with these comorbidities (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.